US kefir maker Lifeway Foods turned down two offers from the French giant – one of its shareholders – last year.

Levy reported R&D expenses of $38.3 million for Q2 2025, down from $39.3 million in the prior year period, attributed to the conclusion of the lorundrostat pivotal program, partially offset by ...

The FDA accepted vepdegestrant’s new drug application for ER+/HER2–, ESR1-mutated advanced breast cancer with a June 5, 2026, ...

Candidates are nominated by political parties or alliances, and the election is conducted by members of both houses of ...

BJP national president JP Nadda said it is important to regularly hold meetings of the parliamentary standing committees so ...

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling ...

Discover key insights from Xenon Pharmaceuticals' Q2 2025 earnings call, including milestones in epilepsy, depression trials, and a strong cash ...

The National Democratic Alliance (NDA) is likely to announce its vice presidential candidate today after former Vice President Jagdeep Dhankhar resigned earlier in July. Bangladesh’s Chief Advisor Muh ...

Panneerselvam has quit the NDA, causing significant ripples in Tamil Nadu's political landscape. Despite his departure, the ...

The NDA, led by the BJP, is expected to announce its vice-presidential candidate between August 12 and 13, as final ...

FDA accepts a new formulation of piflufolastat F 18, enhancing prostate cancer imaging access and efficiency, with a target ...

Q2 2025 Management View CEO Yu-Hsin Lin reported "excellent progress in the quarter towards advancing Tinlarebant narrowband in patients living with Stargardt's disease and geographic atrophy," ...